Recombinant Human WASL Protein, N-His

Introduction

Recombinant Human WASL Protein, also known as Wiskott-Aldrich syndrome protein-like (WASL), is a protein that plays a crucial role in the regulation of actin cytoskeleton dynamics. This protein is encoded by the WASL gene and is a member of the Wiskott-Aldrich syndrome protein (WASP) family. WASL is involved in a variety of cellular processes, including cell motility, adhesion, and immune response. In this article, we will explore the structure, activity, and applications of Recombinant Human WASL Protein.

Structure of Recombinant Human WASL Protein

Recombinant Human WASL Protein is a 559 amino acid protein with a molecular weight of approximately 62 kDa. It contains multiple domains, including an N-terminal EVH1 domain, a central proline-rich region, and a C-terminal VCA domain. The EVH1 domain is responsible for binding to the proline-rich region of other proteins, while the VCA domain is involved in actin binding and polymerization. The proline-rich region acts as a linker between the EVH1 and VCA domains, and also contains binding sites for other proteins.

Activity of Recombinant Human WASL Protein

Recombinant Human WASL Protein is a key regulator of the actin cytoskeleton, which is essential for cell motility and shape. WASL interacts with multiple proteins, including actin, to promote actin polymerization and the formation of actin filaments. This process is important for cell migration, adhesion, and immune response. In addition, WASL has been shown to play a role in cell signaling pathways, such as the Wnt signaling pathway, which is involved in cell proliferation and differentiation.

Applications of Recombinant Human WASL Protein

1. Research tool in cell biology: Recombinant Human WASL Protein is commonly used as a research tool to study the role of WASL in various cellular processes. It can be used to investigate the effects of WASL on actin dynamics, cell motility, and signaling pathways. Recombinant WASL can also be used to study the interactions between WASL and other proteins.

2. Therapeutic applications: Mutations in the WASL gene have been linked to Wiskott-Aldrich syndrome, a rare genetic disorder characterized by immune deficiency, eczema, and low platelet count. Recombinant Human WASL Protein has been used in pre-clinical studies as a potential treatment for this syndrome. It has also shown promise in the treatment of other diseases, such as cancer, where actin dynamics play a role.

3. Diagnostic tool: Recombinant Human WASL Protein can be used as an antigen in diagnostic tests for Wiskott-Aldrich syndrome. Antibodies against WASL can be used to detect the presence of the protein in patient samples, which can aid in the diagnosis of the disease.

4. Production of recombinant antibodies: The EVH1 domain of WASL has been used to produce recombinant antibodies, known as nanobodies, that specifically bind to the proline-rich region of WASL. These nanobodies can be used as research tools or potential therapeutics for diseases involving WASL.

Conclusion

Recombinant Human WASL Protein is a crucial regulator of actin cytoskeleton dynamics, playing a role in cell motility, adhesion, and immune response. Its structure, activity, and applications make it a valuable tool in cell biology research and a potential therapeutic for various diseases. Further studies on this protein may uncover new insights into its role in cellular processes and lead to the development of novel treatments for diseases associated with WASL dysfunction.